Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERES trial: trastuzumab added to chemo-immunotherapy for HER2-positive esophageal squamous cell carcinoma
2021-003415-26Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of trastuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Rigshospitalet. Primary endpoint: 6-month progression-free survival (PFS) by iRECIST. Started Jul 2021; status: active.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2021-003415-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003415-26.